<- Go Home
BiomX Inc.
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company’s product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Market Cap
$17.0M
Volume
88.9K
Cash and Equivalents
$23.5M
EBITDA
-$31.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$8.55
52 Week Low
$0.48
Dividend
N/A
Price / Book Value
0.88
Price / Earnings
-0.25
Price / Tangible Book Value
4.29
Enterprise Value
$21.9M
Enterprise Value / EBITDA
-0.78
Operating Income
-$32.3M
Return on Equity
37.81%
Return on Assets
-43.41
Cash and Short Term Investments
$23.5M
Debt
$9.7M
Equity
$37.9M
Revenue
N/A
Unlevered FCF
-$18.3M
Sector
Biotechnology
Category
N/A